A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder

被引:7
|
作者
Meng, Meng [1 ]
Bai, Chen [2 ]
Wan, Bo [3 ]
Zhao, Luqing [1 ]
Li, Zhe [1 ]
Li, Danyan [1 ]
Zhang, Shengsheng [1 ]
机构
[1] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Digest Ctr, Beijing, Peoples R China
[2] Beijing Univ Chinese Med, Beijing, Peoples R China
[3] Kings Coll London, Guys Hosp, Ctr Stem Cells & Regenerat Med, London, England
关键词
GASTROENTEROLOGY MONOGRAPH; AMERICAN-COLLEGE; MANAGEMENT; CANCER; IBD;
D O I
10.1155/2021/4579850
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background and Objective. Irritable bowel syndrome (IBS) is a prevalent disorder of the gastrointestinal system with complex pathogenesis. Shenling Baizhu powder (SLBZP) is a Chinese herbal compound with multicomponent and multitarget characteristics. Increasing volumes of evidence demonstrate that it has a notable therapeutic impact on IBS. This study therefore is aimed at exploring the potential effective components of SLBZP and their mechanisms in IBS treatment utilizing network pharmacology. Methods. Metabolomics was used to detect the secondary metabolites in SLBZP; the target protein was acquired by target fishing according to the compound's structure. The SymMap database was used to search herbal medicines for the target protein. The target gene of IBS gave rise to the common gene protein which is the potential target of SLBZP in IBS therapy. The interactions between target proteins were analyzed in a STRING database, the protein relationship network was analyzed using Cytoscape software, and the Kyoto Encyclopedia of Genes and Genomes enrichment analysis of the core target gene group was carried out in a DAVID database in order to construct the "compound-traditional Chinese medicine/ molecule-target-pathway" network. Molecular docking was used to verify the core protein and its related small molecular compounds. Result. There were 129 types of secondary metabolites in SLBZP. 80 target proteins of these metabolites were potential core targets for IBS treatment including acetylcholinesterase (AChE), arachidonate-5-lipoxygenase (ALOX5), B-cell lymphoma-2 (BCL2), recombinant cyclin D1 (CCND1), and catenin-beta 1 (CTNNB1), among others. Results from these targets indicated that the most enriched pathway was the tumor necrosis factor (TNF) signaling pathway (p < 0:001) and that the most abundant pathway was signal transduction. In the network nodes of the TNF signaling pathway, the Chinese medicines with the highest aggregation were Lablab semen album and Glycyrrhizae radix et rhizoma (degree = 11). The small molecules with the highest aggregation were oxypeucedanin and 3,5,6,7,8,3',4'- heptamethoxyflavone (degree = 4). Molecular docking results confirmed that daidzein 7-O-glucoside (daidzin) had the highest degree of binding to TNF proteins in the TNF signaling pathway. Conclusion. This study shows that SLBZP can treat IBS by influencing multiple targets and pathways, of which the TNF signaling pathway may be the most significant. This typifies the pharmacological characteristics of traditional Chinese medicine, i.e., multiple targets, numerous pathways, and specific therapeutic effects on diseases. SLBZP can therefore be used as a candidate drug for clinical IBS by intervening in human signal transduction.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Network Pharmacology-Based Study on the Mechanism of Ginsenoside Rh2 in Glioma Treatment
    Wu, Xue
    Qin, Xiujiao
    Dong, Han
    NATURAL PRODUCT COMMUNICATIONS, 2022, 17 (08)
  • [22] A Network Pharmacology-Based Study on the Hepatoprotective Effect of Fructus Schisandrae
    Hong, Ming
    Zhang, Yongsheng
    Li, Sha
    Tan, Hor Yue
    Wang, Ning
    Mu, Shuzhen
    Hao, Xiaojiang
    Feng, Yibin
    MOLECULES, 2017, 22 (10)
  • [23] Network Pharmacology Identifies the Mechanisms of Action of Tongxie Anchang Decoction in the Treatment of Irritable Bowel Syndrome with Diarrhea Predominant
    Tan, Xiang
    Pei, Wenjing
    Xie, Chune
    Wang, Zhibin
    Mao, Tangyou
    Zhao, Xingjie
    Kou, Fushun
    Lu, Qiongqiong
    Sun, Zhongmei
    Xue, Xiaoxuan
    Li, Junxiang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
  • [24] Irritable Bowel Syndrome: a Population Based Study
    Khoshkrood-Mansoori, Babak
    Pourhoseingholi, Mohamad Amin
    Safaee, Azadeh
    Moghimi-Dehkordi, Bijan
    Sedigh-Tonekaboni, Babk
    Pourhoseingholi, Asma
    Habibi, Manijeh
    Zali, Mohamad Reza
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 413 - 418
  • [25] Network pharmacology-based study on the active substances and mechanism of Nao An Capsule in treatment of ischemic stroke
    Chen, Chen
    Li, Hui-Ling
    Yi, Yuan
    Fan, Hua-Jun
    Chen, Chao
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2019, 31
  • [26] Exploration the mechanism of Shenling Baizhu San in the treatment of chronic obstructive pulmonary disease based on UPLC-Q-TOF-MS/MS, network pharmacology and in vitro experimental verification
    Gao, Zu
    Wang, Jiayun
    Lu, Guangying
    Wu, Qiaolan
    Wang, Shijun
    Wu, Xiaolin
    Ou, Chunxue
    Wu, Zhichun
    Yu, Huayun
    Wang, Yuan
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 324
  • [28] Irritable bowel syndrome: treatment based on pathophysiology and biomarkers
    Camilleri, Michael
    Boeckxstaens, Guy
    GUT, 2023, 72 (03) : 590 - 599
  • [29] A CONTROLLED BEHAVIORAL TREATMENT STUDY OF IRRITABLE BOWEL SYNDROME
    LYNCH, PM
    ZAMBLE, E
    BEHAVIOR THERAPY, 1989, 20 (04) : 509 - 523
  • [30] Network Pharmacology-Based Study on the Mechanism of Bushen-Jianpi Decoction in Liver Cancer Treatment
    Wu, Rong
    Li, Xiao-Yan
    Wang, Wen-Hai
    Cai, Fei-Fei
    Chen, Xiao-Le
    Yang, Meng-Die
    Pan, Qiu-Sha
    Chen, Qi-Long
    Zhou, Rong-Yao
    Su, Shi-Bing
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 2019